IBM Watson Health to integrate MedyMatch's AI-based intracranial bleeding app into cognitive imaging offerings

IBM Watson Health and MedyMatch Technology entered into a five-year licensing agreement to bring the latter's artificial intelligence (AI)-based clinical decision support app to imaging experts working in acute-care settings "to help doctors identify instances of intracranial bleeding as a result of head trauma and stroke," the companies announced Thursday. Financial terms of the deal were not disclosed.

Gene Saragnese, chief executive at MedyMatch, said "engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering 'AI to the bedside' where I believe the future of healthcare lies." He added that "improvements in the interpretation of data will lead to better decisions…better outcomes for patients and lower cost for healthcare."

Under the agreement, IBM Watson Health's Imaging group will initially distribute the MedyMatch brain-bleed detection app globally. The companies then plan to develop interoperability between the app and IBM Watson Health Imaging's offerings.

According to the companies, the MedyMatch algorithm uses "deep learning, machine vision, patient data and clinical insights to automatically highlight… regions of interest that could indicate the potential presence of cerebral bleeds." MedyMatch is currently conducting a clinical trial for the app and is working towards FDA approval.

Separately on Thursday, IBM Watson Heath announced a five-year alliance with IDx to advance eye health through cognitive computing applications. 

Did you like this article?